FDA Acceptance of Lacosamide Supplement by MSN Labs
The FDA has accepted a supplemental application for Lacosamide submitted by MSN Labs.
Asset / Drug
Drug and asset intelligence for Lacosamide with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Aurobindo Pharma's application for Lacosamide (ANDA204994) has received an Abbreviated Approval (AP) status from the FDA.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.